These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11235144)

  • 1. [Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
    Nakazato H; Suzuki K; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):6-12. PubMed ID: 11235144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flutamide has no effect on adrenal androgen response to acute ACTH stimulation in patients with prostatic cancer.
    Carlström K; Pousette A; Stege R
    Prostate; 1990; 17(3):219-25. PubMed ID: 1978301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
    Nishii M; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Androl; 2012; 33(6):1233-8. PubMed ID: 22492843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D; Dubé D; Bélanger A; Labrie F
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer.
    Balzano S; Cappa M; Migliari R; Scarpa RM; Danielli E; Campus G; Pintus C; Sica V; Usai E; Martino E
    J Endocrinol Invest; 1988 Nov; 11(10):693-6. PubMed ID: 2852689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R; Lachance R; Dupont A; Labrie F
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist.
    Kitahara S; Yoshida K; Ishizaka K; Kageyama Y; Kawakami S; Tsujii T; Oshima H
    Endocr J; 1997 Aug; 44(4):527-32. PubMed ID: 9447285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
    Ayub M; Levell MJ
    Clin Endocrinol (Oxf); 1990 Mar; 32(3):329-39. PubMed ID: 2140542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
    Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
    Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of adrenal androgens in prostate regression in rats treated with an antiandrogen and an LHRH agonist.
    Foldesy RG; Vanderhoof MM; Canton LE; Hahn DW
    Prostate; 1986; 9(3):227-35. PubMed ID: 3534825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer.
    Kitahara S; Umeda H; Yano M; Koga F; Sumi S; Moriguchi H; Hosoya Y; Honda M; Yoshida K
    Endocr J; 1999 Oct; 46(5):659-64. PubMed ID: 10670751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.